JO
CRBP icon

John Overdeck’s Corbus Pharmaceuticals CRBP Stock Holding History

John Overdeck’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,480
Closed -$102K – 4634
2025
Q4 		$102K Sell
12,480
-13,977
-53% -$173K ﹤0.01% 3855
2025
Q3 		$335K Sell
26,457
-19,044
-42% -$181K ﹤0.01% 3171
2025
Q2 		$314K Sell
45,501
-75,663
-62% -$550K ﹤0.01% 2774
2025
Q1 		$643K Sell
121,164
-13,011
-10% -$115K ﹤0.01% 2406
2024
Q4 		$1.58M Buy
134,175
+91,205
+212% +$1.53M ﹤0.01% 1870
2024
Q3 		$886K Buy
+42,970
New +$2.2M ﹤0.01% 2197
2023
Q1 		– Sell
-19,006
Closed -$63K – 2997
2022
Q4 		$63K Buy
19,006
+14,934
+367% +$57.5K ﹤0.01% 2566
2022
Q3 		$20K Buy
4,072
+1,520
+60% +$10.7K ﹤0.01% 2380
2022
Q2 		$19K Buy
+2,552
New +$24.7K ﹤0.01% 2411
2021
Q4 		– Sell
-3,494
Closed -$107K – 4370
2021
Q3 		$107K Buy
+3,494
New +$138K ﹤0.01% 4076
2020
Q3 		– Sell
-6,279
Closed -$1.58M – 3163
2020
Q2 		$1.58M Buy
+6,279
New +$1.27M 0.01% 1226

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

John Overdeck's CRBP Position: Q1 2026 in Review

John Overdeck sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 12,480 shares — an estimated $102K sold.

John Overdeck first reported a position in CRBP in Q2 2020 and held it in 11 quarters. The position peaked at $1.58M in Q4 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • John Overdeck reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 12,480 Corbus Pharmaceuticals shares in Q1 2026, an estimated $102K.
  • John Overdeck first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 11 quarters.
  • John Overdeck's Corbus Pharmaceuticals position peaked at $1.58M in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.